Rituximab therapy in lupus nephritis: current clinical evidence (Q37737138)

22 August 2017

1 reference

title

Rituximab therapy in lupus nephritis: current clinical evidence (English)

1 reference

22 August 2017

1 reference

1 reference

Manuel Ramos-Casals

1

0 references

Munther A. Khamashta

8

object named as

Munther A Khamashta

1 reference

22 August 2017

Candido Diaz-Lagares

2

1 reference

22 August 2017

Maria-Jose Soto-Cardenas

3

1 reference

22 August 2017

Pilar Brito-Zeron

4

1 reference

22 August 2017

María-José Cuadrado

5

1 reference

22 August 2017

Giovanni Sanna

6

1 reference

22 August 2017

Laura Bertolaccini

7

1 reference

22 August 2017

1 June 2011

1 reference

Clinical Reviews in Allergy & Immunology

22 August 2017

1 reference

22 August 2017

40

1 reference

22 August 2017

3

1 reference

22 August 2017

159-169

1 reference

https://scigraph.springernature.com/pub.10.1007/s12016-010-8205-3

22 August 2017

0 references

cites work

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

How to improve morbidity and mortality in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

The B cell in systemic lupus erythaematosus: a rational target for more effective therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

A systematic review of the off-label use of biological therapies in systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Consensus statement on the use of rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Autoimmune diseases induced by TNF-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Autoimmune Diseases Induced by TNF-Targeted Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Rituximab and lupus: Good in real life, bad in controlled trials. comment on the article by Lu et al

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-010-8205-3

Failure of rituximab to treat a lupus flare-up with nephritis

21 January 2018

1 reference

12 December 2020

Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis

1 reference

12 December 2020

Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study

1 reference

12 December 2020

The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials

1 reference

12 December 2020

Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab

1 reference

12 December 2020

Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab

1 reference

12 December 2020

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis

1 reference

12 December 2020

The Long-Term Clinical Course of Systemic Lupus Erythematosus in End-Stage Renal Disease

1 reference

12 December 2020

10.1007/S12016-010-8205-3

Identifiers

DOI

1 reference

22 August 2017

1 reference